From:
Inc42 reporter Tapanjana Rudra featured insights from Columbia Business School Professor Rajeev Kohli in an article examining CrisprBits, a biotech startup leveraging CRISPR-based tools to make critical disease diagnosis faster and more affordable. Kohli, alongside other researchers, discussed how innovations like CrisprBits can shift patient pathways, reduce testing costs, and improve access—particularly in resource-constrained settings. He emphasized that commercial success will depend not only on technological breakthroughs but also on market education, regulatory navigation, and the ability to build trust with healthcare providers and consumers.
